Evidence map›Paper›PMID 37464334›Full record

ArticleBMC cancer2023

Transcriptional analysis of the expression and prognostic value of lipid droplet-localized proteins in hepatocellular carcinoma.

Yize Zhang, Xue Liang, Qinghai Lian, Liwen Liu, Baoyu Zhang, Zihui Dong, Kunpeng Liu

Open access · goldAbstract read
In one paragraph

Article in BMC cancer, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
2.0field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

Yize Zhang *Precision Medicine Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Xue Liang *School of Life Science, Beijing University of Chinese Medicine, Beijing, China.
Qinghai Lian *Cell-gene Therapy Translational Medicine Research Center, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
Liwen LiuPrecision Medicine Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Baoyu ZhangDepartment of Neurosurgery, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China. zhangbaoyu0719@163.com.
Zihui DongPrecision Medicine Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China. donghellen@163.com.
Kunpeng LiuCell-gene Therapy Translational Medicine Research Center, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China. liukp@gxu.edu.cn.
First Affiliated Hospital of Zhengzhou University · CNSun Yat-sen University · CNBeijing University of Chinese Medicine · CNGuangxi University · CN

Funding

China Postdoctoral Science Foundation Grant 2019M653189National Natural Science Foundation of China 81901613Natural Science Foundation of Guangdong Province 2020A1515011299Natural Science Foundation of Henan Province-Young Scientists Fund 232300420258the Fundamental Research Funds for the Central Universities 20ykpy28the Joint Construction Project of Medical Science and Technology Research Plan of Henan Province LHGJ20190023
6 · The paper itself

Abstract

The accumulation of lipid droplets (LDs) in hepatocytes is the main pathogenesis in nonalcoholic fatty liver disease (NAFLD), which is also the key risk factor for the progression of hepatocellular carcinoma (HCC). LDs behaviors are demonstrated to be associated with HCC advancement, and are tightly regulated by a subset protein localized on the surface of LDs. However, the role of LDs-localized protein in HCC has been rarely investigated. This study is focused on the transcriptional dynamic and prognostic value of LDs-localized protein in HCC. Firstly, we summarized the known LDs-localized proteins, which are demonstrated by immunofluorescence according to previous studies. Next, by the use of GEPIA/UALCAN/The Human Protein Atlas databases, we screened the transcriptional change in tumor and normal liver tissues, and found that 13 LDs-localized proteins may involve in the progression of HCC. Then we verified the transcriptional changes of 13 LDs-localized proteins by the use of HCC samples. Moreover, based on the assays of fatty liver of mice and human NAFLD liver samples, we found that the hepatic steatosis mainly contributed to the transcriptional change of selected LDs-localized proteins, indicating the involvement of these LDs-localized proteins in the negative role of NAFLD in HCC progression. Finally, we focused on the role of PLIN3 in HCC, and revealed that NAFLD status significantly promoted PLIN3 transcription in HCC tissue. Functional studies revealed that PLIN3 knockdown significantly limited the migration and chemosensitivity of hepatoma cells, suggesting the positive role of PLIN3 in HCC progression. Our study not only revealed the transcriptional change and prognostic value of lipid droplet-localized proteins in HCC, but also built the correlation between HCC and hepatic steatosis.

Indexed as

Carcinoma, HepatocellularLiver NeoplasmsNon-alcoholic Fatty Liver DiseaseHumansLipid Droplet Associated ProteinsLipid DropletsPrognosisProteinsLipid Droplet Associated ProteinsProteinsHCCLDs-localized proteinNAFLD

Identifiers

PMID37464334
PMCPMC10354995
OpenAlexW4384663724

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.